UPLOAD Filing
Caribou Biosciences, Inc.
Date: May 12, 2025 · CIK: 0001619856 · Accession: 0000000000-25-005015
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-287093
Letter
Re: Caribou Biosciences, Inc. Registration Statement on Form S-3 Filed May 8, 2025 File No. 333-287093 Dear Rachel E. Haurwitz Ph.D.:
May 12, 2025
Rachel E. Haurwitz, Ph.D. President and Chief Executive Officer Caribou Biosciences, Inc. 2929 7th Street, Suite 105 Berkeley, California 94710
This is to advise you that we have not reviewed and will not review your registration statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Tim Buchmiller at 202-551-3635 with any questions.
Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
cc: Ashok W. Mukhey, Esq.
Show Raw Text
<DOCUMENT> <TYPE>TEXT-EXTRACT <SEQUENCE>2 <FILENAME>filename2.txt <TEXT> May 12, 2025 Rachel E. Haurwitz, Ph.D. President and Chief Executive Officer Caribou Biosciences, Inc. 2929 7th Street, Suite 105 Berkeley, California 94710 Re: Caribou Biosciences, Inc. Registration Statement on Form S-3 Filed May 8, 2025 File No. 333-287093 Dear Rachel E. Haurwitz Ph.D.: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tim Buchmiller at 202-551-3635 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Ashok W. Mukhey, Esq. </TEXT> </DOCUMENT>